Brokerages offer mixed views on Sun Pharma post steady Q3; buy, sell, hold?

Brokerages remained divided on Sun Pharmaceuticals after it delivered a steady and in line third quarter earnings performance for the financial year 2024-25 (Q3FY25), with some bullish on specialty and domestic businesses, while others were
Read more...